Document Detail

Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients.
MedLine Citation:
PMID:  17116836     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Mucous membrane pemphigoid (MMP), also known as cicatricial pemphigoid, is a serious, autoimmune, blistering disorder that can result in blindness and other complications as a result of scarring of the mucous membranes. Effective treatment modalities are often toxic. Herein, we describe a novel therapeutic approach that is based on 2 reports in the literature of the successful use of etanercept to treat MMP. OBSERVATIONS: Three patients with MMP were treated with subcutaneous injections of 25 mg of etanercept twice weekly. All 3 patients had oral mucosal involvement, and 1 had severe, recalcitrant, ocular disease. Oral mucosal disease improved in all 3 patients. The patient with ocular involvement experienced stabilization of progression. CONCLUSIONS: Effective treatment modalities for MMP are often toxic. Etanercept may be an effective treatment option for MMP of the oral and ocular mucous membranes. This therapy should be considered as an alternative treatment option for patients who would require other aggressive systemic treatments, such as cyclophosphamide, corticosteroids, azathioprine sodium, and intravenous immunoglobulin.
Maria J Canizares; David I Smith; Michael S Conners; Kenneth J Maverick; Michael P Heffernan
Related Documents :
20233916 - Intervention to reduce unnecessary dispensing of short-acting {beta}-agonists in patien...
19642026 - Selective immune adsorption treatment of severe guillain barré syndrome in the intensi...
25151536 - Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: populat...
22639426 - One-year outcomes of consecutive patients treated by endeavor zotarolimus and resolute ...
18061806 - Mastopexy after massive weight loss: dermal suspension and selective auto-augmentation.
24215216 - Correlation between maximum phonetically balanced word recognition score and pure-tone ...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Archives of dermatology     Volume:  142     ISSN:  0003-987X     ISO Abbreviation:  Arch Dermatol     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-11-22     Completed Date:  2006-12-15     Revised Date:  2008-03-17    
Medline Journal Info:
Nlm Unique ID:  0372433     Medline TA:  Arch Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1457-61     Citation Subset:  AIM; IM    
Division of Dermatology, Department of Ophthalmology, Washington University School of Medicine, St Louis, MO, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Conjunctival Diseases / complications,  diagnosis,  drug therapy,  pathology
Diagnosis, Differential
Immunoglobulin G / administration & dosage,  therapeutic use*
Immunologic Factors / administration & dosage,  therapeutic use*
Injections, Subcutaneous
Middle Aged
Pemphigoid, Benign Mucous Membrane / complications,  diagnosis,  drug therapy*,  pathology
Receptors, Tumor Necrosis Factor / administration & dosage,  therapeutic use*
Severity of Illness Index
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Immunoglobulin G; 0/Immunologic Factors; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment...
Next Document:  Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G...